{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T05:40:24Z","timestamp":1790487624012,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["16888"],"award-info":[{"award-number":["16888"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101016726"],"award-info":[{"award-number":["101016726"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","award":["777377"],"award-info":[{"award-number":["777377"]}],"id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jhepr.2021.100284","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T03:19:37Z","timestamp":1617074377000},"page":"100284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets"],"prefix":"10.1016","volume":"3","author":[{"given":"Cristiana","family":"Bianco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Casirati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Malvestiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2021.100284_bib1","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib2","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/liv.14430","article-title":"Redefining fatty liver disease classification in 2020","volume":"40","author":"Valenti","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib4","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom and United States for the period 2016\u20132030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1053\/j.gastro.2017.01.003","article-title":"Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation","volume":"152","author":"Goldberg","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jhep.2013.08.011","article-title":"Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team","volume":"60","author":"Dyson","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-230X-14-166","article-title":"Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease","volume":"14","author":"Haflidadottir","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100284_bib9","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.cgh.2017.11.045","article-title":"Alcoholic liver disease replaces hepatitis C virus infection as the leading indication for liver transplantation in the United States","volume":"16","author":"Cholankeril","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/tri.13358","article-title":"2018 annual report of the European liver transplant registry (ELTR)\u201350-year evolution of liver transplantation","volume":"31","author":"Adam","year":"2018","journal-title":"Transpl Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging human genetics to identify potential new treatments for fatty liver disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00281-009-0152-9","article-title":"The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?","volume":"31","author":"Valenti","year":"2009","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhepr.2021.100284_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1530-0277.2008.00827.x","article-title":"Molecular mechanisms of alcoholic fatty liver","volume":"33","author":"Purohit","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhepr.2021.100284_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhepr.2021.100284_bib15","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib16","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/hep.20821","article-title":"Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice","volume":"42","author":"You","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib17","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/hep.20399","article-title":"Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage","volume":"40","author":"Nakajima","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib18","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jhep.2006.05.009","article-title":"Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model","volume":"45","author":"Ji","year":"2006","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib19","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib20","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.cgh.2019.01.027","article-title":"Prevalence and risk factors of significant fibrosis in patients with nonalcoholic fatty liver without steatohepatitis","volume":"17","author":"Pelusi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib21","first-page":"1","article-title":"The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success","author":"Drenth","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jhepr.2021.100284_bib22","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.jhep.2020.02.020","article-title":"Update on NAFLD genetics: from new variants to the clinic","volume":"72","author":"Trepo","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/hep.31229","article-title":"Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology","volume":"72","author":"Sookoian","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib24","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2174\/1381612826666200122151251","article-title":"Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease","volume":"26","author":"Cespiati","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jhepr.2021.100284_bib25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.molmet.2019.01.013","article-title":"Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice","volume":"22","author":"Linden","year":"2019","journal-title":"Mol Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/gutjnl-2011-301239","article-title":"Genetic determinants of alcoholic liver disease","volume":"61","author":"Stickel","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100284_bib27","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2021.100284_bib28","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/hep.23622","article-title":"Homozygosity for the PNPLA3\/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"51","author":"Valenti","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/ng.488","article-title":"Variant in PNPLA3 is associated with alcoholic liver disease","volume":"42","author":"Tian","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib31","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A\u00a0genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib32","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1002\/hep.26767","article-title":"Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data","volume":"59","author":"Trepo","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib33","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jhep.2017.01.018","article-title":"Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis","volume":"67","author":"Atkinson","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib34","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1016\/S0168-8278(16)01634-2","article-title":"GS03\u2013a genome-wide association study identifies PNPLA3 and SLC38A4 as risk loci for alcoholic hepatitis","volume":"64","author":"Atkinson","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib35","doi-asserted-by":"crossref","first-page":"7892","DOI":"10.1073\/pnas.1003585107","article-title":"A\u00a0feed-forward loop amplifies nutritional regulation of PNPLA3","volume":"107","author":"Huang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100284_bib36","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1074\/jbc.RA118.002333","article-title":"Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets","volume":"293","author":"Mitsche","year":"2018","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhepr.2021.100284_bib37","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1093\/hmg\/ddu121","article-title":"PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells","volume":"23","author":"Pirazzi","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib38","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jhepr.2021.100284_bib39","first-page":"5212","article-title":"PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis","volume":"25","author":"Pingitore","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib40","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/hep.29041","article-title":"The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells","volume":"65","author":"Bruschi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib41","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib42","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.27490","article-title":"Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease","volume":"61","author":"Dongiovanni","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib43","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/hep.30583","article-title":"PNPLA3, CGI-58, and inhibition of hepatic triglyceride hydrolysis in mice","volume":"69","author":"Wang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib44","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1038\/s41598-019-47737-w","article-title":"The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids","volume":"9","author":"Prill","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100284_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001324","article-title":"Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits","volume":"7","author":"Speliotes","year":"2011","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087523","article-title":"Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease","volume":"9","author":"Petta","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jhepr.2021.100284_bib47","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/joim.12719","article-title":"Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver","volume":"283","author":"Dongiovanni","year":"2018","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jhepr.2021.100284_bib48","doi-asserted-by":"crossref","first-page":"E1126","DOI":"10.1210\/jc.2010-2017","article-title":"Hepatic glucokinase expression is associated with lipogenesis and fatty liver in humans","volume":"96","author":"Peter","year":"2011","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib49","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1093\/hmg\/ddp357","article-title":"The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver","volume":"18","author":"Beer","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib50","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2020.08.027","article-title":"rs641738C>T near MBOAT7 is associated with liver fat, ALT, and fibrosis in NAFLD: a meta-analysis","volume":"74","author":"Teo","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib52","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa1712191","article-title":"A\u00a0protein-truncating HSD17B13 variant and protection from chronic liver disease","volume":"378","author":"Abul-Husn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhepr.2021.100284_bib53","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.30350","article-title":"HSD17B13 is a hepatic retinol dehydrogenase associated with histological features\u00a0of non-alcoholic fatty liver disease","volume":"69","author":"Ma","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/hep.30996","article-title":"Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers","volume":"72","author":"Stickel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008629","article-title":"A\u00a0missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease","volume":"16","author":"Emdin","year":"2020","journal-title":"Plos Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib56","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1053\/j.gastro.2020.12.011","article-title":"Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study","volume":"160","author":"Emdin","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib57","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1053\/j.gastro.2020.06.014","article-title":"Genome-wide association study for alcohol-related cirrhosis identifies risk loci in MARC1 and HNRNPUL1","volume":"159","author":"Innes","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib58","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1038\/s41598-017-04991-0","article-title":"MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals","volume":"7","author":"Donati","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100284_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30587-0","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","author":"Bianco","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib60","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/liv.13972","article-title":"Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease","volume":"39","author":"Pelusi","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib61","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1053\/j.gastro.2020.12.023","article-title":"Exome-wide association study on alanine aminotransferase identifies sequence variants in the GPAM and APOE associated with fatty liver disease","volume":"160","author":"Jamialahmadi","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jhep.2020.04.003","article-title":"Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically-characterised cohort","volume":"73","author":"Anstee","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TACG.S187922","article-title":"A\u00a0two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption","volume":"12","author":"Mancina","year":"2019","journal-title":"Appl Clin Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib64","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1530-0277.2012.01925.x","article-title":"Polymorphisms of the CD14 genes are associated with susceptibility to alcoholic liver disease in Greek patients","volume":"37","author":"Nezi","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhepr.2021.100284_bib65","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib66","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib67","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2016.07.045","article-title":"The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans","volume":"65","author":"Luukkonen","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib68","doi-asserted-by":"crossref","first-page":"102658","DOI":"10.1016\/j.ebiom.2020.102658","article-title":"Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes","volume":"52","author":"Meroni","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2021.100284_bib69","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1194\/jlr.P090449","article-title":"PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients","volume":"60","author":"Dongiovanni","year":"2019","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2021.100284_bib70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nmeth.2857","article-title":"Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects","volume":"11","author":"Shen","year":"2014","journal-title":"Nat Methods"},{"key":"10.1016\/j.jhepr.2021.100284_bib71","article-title":"Paradoxical dissociation between hepatic fat content and de novo lipogenesis due to PNPLA3 sequence variant","author":"Margherita Mancina","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib72","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and nonalcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib73","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jhep.2015.07.036","article-title":"Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: results from the WELCOME trial","volume":"63","author":"Scorletti","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib74","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.29298","article-title":"Mutant PNPLA3 I148M protein as pharmacological target for liver disease","volume":"66","author":"Valenti","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib75","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.31569","article-title":"Oligonucleotide-based therapeutics: an emerging strategy for the treatment of chronic liver diseases","volume":"73","author":"Alkhouri","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib76","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.28370","article-title":"The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage","volume":"63","author":"Donati","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/cells9102247","article-title":"Discovery and targeting of the signaling controls of PNPLA3 to effectively reduce transcription, expression, and function in pre-clinical NAFLD\/NASH settings","volume":"9","author":"Schwartz","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jhepr.2021.100284_bib78","first-page":"1687","article-title":"PNPLA3 I148M variant influences circulating retinol in adults with nonalcoholic fatty liver disease or obesity","volume":"145","author":"Mondul","year":"2015","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.jhepr.2021.100284_bib79","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2015.10.016","article-title":"MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease","volume":"64","author":"Petta","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib80","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.cmet.2019.11.013","article-title":"Macrophage MerTK promotes liver fibrosis in nonalcoholic steatohepatitis","volume":"31","author":"Cai","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib81","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.cmet.2020.03.010","article-title":"Cholesterol stabilizes TAZ in hepatocytes to promote experimental non-alcoholic steatohepatitis","volume":"31","author":"Wang","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib82","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1038\/ncomms12757","article-title":"MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C","volume":"7","author":"Thabet","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100284_bib83","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1002\/hep.29064","article-title":"The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B","volume":"65","author":"Thabet","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib84","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1038\/s41598-019-39998-2","article-title":"Rare pathogenic variants predispose to hepatocellular carcinoma in nonalcoholic fatty liver disease","volume":"9","author":"Pelusi","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100284_bib85","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jsb.2019.04.006","article-title":"MBOAT7 is anchored to endomembranes by six transmembrane domains","volume":"206","author":"Caddeo","year":"2019","journal-title":"J\u00a0Struct Biol"},{"key":"10.1016\/j.jhepr.2021.100284_bib86","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ajhg.2016.07.019","article-title":"Mutations in MBOAT7, encoding lysophosphatidylinositol acyltransferase I, lead to intellectual disability accompanied by epilepsy and autistic features","volume":"99","author":"Johansen","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib87","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1091\/mbc.e12-09-0673","article-title":"LPIAT1 regulates arachidonic acid content in phosphatidylinositol and is required for cortical lamination in mice","volume":"23","author":"Lee","year":"2012","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.jhepr.2021.100284_bib88","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1365-2443.2008.01212.x","article-title":"Member of the membrane-bound O-acyltransferase (MBOAT) family encodes a lysophospholipid acyltransferase with broad substrate specificity","volume":"13","author":"Matsuda","year":"2008","journal-title":"Genes Cells"},{"key":"10.1016\/j.jhepr.2021.100284_bib89","doi-asserted-by":"crossref","first-page":"30235","DOI":"10.1074\/jbc.M806194200","article-title":"Lysophospholipid acyltransferases and arachidonate recycling in human neutrophils","volume":"283","author":"Gijon","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhepr.2021.100284_bib90","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/gutjnl-2020-320646","article-title":"LPIAT1\/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover","volume":"70","author":"Tanaka","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100284_bib91","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/gutjnl-2020-320853","article-title":"Loss of hepatic Mboat7 leads to liver fibrosis","volume":"70","author":"Thangapandi","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100284_bib92","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49882","article-title":"Obesity-linked suppression of membrane-bound O-Acyltransferase 7 (MBOAT7) drives non-alcoholic fatty liver disease","volume":"8","author":"Helsley","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.jhepr.2021.100284_bib93","article-title":"Hepatic deletion of Mboat7 (Lpiat1) causes activation of SREBP-1c and fatty liver","author":"Xia","year":"2020","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jhepr.2021.100284_bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2005.11.003","article-title":"In silico patent searching reveals a new cannabinoid receptor","volume":"27","author":"Baker","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jhepr.2021.100284_bib95","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.bbrc.2007.08.078","article-title":"Identification of GPR55 as a lysophosphatidylinositol receptor","volume":"362","author":"Oka","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jhepr.2021.100284_bib96","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/hep.31290","article-title":"The L-alpha-lysophosphatidylinositol\/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis","volume":"73","author":"Fondevila","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib97","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib98","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/ng.3855","article-title":"Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci","volume":"49","author":"Stender","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jhepr.2021.100284_bib99","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib100","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100284_bib101","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/hep.23046","article-title":"Adipokines in liver diseases","volume":"50","author":"Marra","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib102","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/liv.13185","article-title":"Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?","volume":"36","author":"Valenti","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib103","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.2337\/db16-0287","article-title":"Increased interleukin-32 levels in obesity promote adipose tissue inflammation and extracellular matrix remodeling: effect of weight loss","volume":"65","author":"Catalan","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.jhepr.2021.100284_bib104","doi-asserted-by":"crossref","first-page":"154832","DOI":"10.1016\/j.cyto.2019.154832","article-title":"Serum levels of IL-32 in patients with type 2 diabetes mellitus and its relationship with TNF-alpha and IL-6","volume":"125","author":"Fadaei","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.jhepr.2021.100284_bib105","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1002\/hep.24285","article-title":"Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis","volume":"53","author":"Moschen","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib106","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1038\/s41467-018-05782-5","article-title":"Intracellular interleukin-32gamma mediates antiviral activity of cytokines against hepatitis B virus","volume":"9","author":"Kim","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhepr.2021.100284_bib107","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1136\/gutjnl-2019-319226","article-title":"Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker","volume":"69","author":"Baselli","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2021.100284_bib108","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/hep.31609","article-title":"Identification of a metabolic, transcriptomic and molecular signature of PNPLA3-mediated acceleration of steatohepatitis","volume":"73","author":"Banini","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib109","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/hep4.1396","article-title":"Interleukin-32 contributes to human nonalcoholic fatty liver disease and insulin resistance","volume":"3","author":"Dali-Youcef","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2021.100284_bib110","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3892\/etm.2017.4596","article-title":"Interleukin-32 promotes lipid accumulation through inhibition of cholesterol efflux","volume":"14","author":"Xu","year":"2017","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhepr.2021.100284_bib111","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar2074","article-title":"Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases","volume":"8","author":"Shoda","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jhepr.2021.100284_bib112","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jir.2018.0173","article-title":"Single triglyceride-rich meal destabilizes barrier functions and initiates inflammatory processes of endothelial cells","volume":"40","author":"Gorzelak-Pabis","year":"2020","journal-title":"J\u00a0Interferon Cytokine Res"},{"key":"10.1016\/j.jhepr.2021.100284_bib113","doi-asserted-by":"crossref","first-page":"35556","DOI":"10.1074\/jbc.M112.400911","article-title":"Intracellular interaction of interleukin (IL)-32alpha with protein kinase Cepsilon (PKCepsilon ) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells","volume":"287","author":"Kang","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhepr.2021.100284_bib114","doi-asserted-by":"crossref","first-page":"34733","DOI":"10.1074\/jbc.M403886200","article-title":"Suppressor of cytokine signaling 3 is a physiological regulator of adipocyte insulin signaling","volume":"279","author":"Shi","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jhepr.2021.100284_bib115","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/liv.14333","article-title":"Uncovering the genetics of cirrhosis: new plots for the usual suspects","volume":"40","author":"Valenti","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib116","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1038\/srep02960","article-title":"IL-32-PAR2 axis is an innate immunity sensor providing alternative signaling for LPS-TRIF axis","volume":"3","author":"Nakayama","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2021.100284_bib117","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","article-title":"Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease","volume":"25","author":"Loomba","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib118","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/liv.14383","article-title":"Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease","volume":"40","author":"Addolorato","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib119","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/liv.14377","article-title":"Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis","volume":"40","author":"Lang","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/liv.14723","article-title":"Targeting pathobionts for the treatment of alcohol-associated liver disease","volume":"41","author":"Lang","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib121","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib122","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.2174\/1381612811319290011","article-title":"Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target","volume":"19","author":"Miele","year":"2013","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jhepr.2021.100284_bib123","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib124","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","article-title":"Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development","volume":"71","author":"Mouries","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/s42255-019-0074-3","article-title":"Metabolic Messengers: fibroblast growth factor 15\/19","volume":"1","author":"Gadaleta","year":"2019","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhepr.2021.100284_bib126","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.dld.2018.11.083","article-title":"FXR rs35724 G>C variant modulates cholesterol levels, carotid atherosclerosis and liver damage in non-alcoholic fatty liver","volume":"51","author":"Grimaudo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2021.100284_bib127","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrgastro.2018.24","article-title":"Probiotics, bile acids and gastrointestinal carcinogenesis","volume":"15","author":"Jia","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib128","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100284_bib129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jhep.2019.10.011","article-title":"beta-Klotho gene variation is associated with liver damage in children with NAFLD","volume":"72","author":"Dongiovanni","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhepr.2021.100284_bib130","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2021.100284_bib131","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and safety of aldafermin, an engineered FGF19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2021.100284_bib132","doi-asserted-by":"crossref","first-page":"102719","DOI":"10.1016\/j.ebiom.2020.102719","article-title":"Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor","volume":"54","author":"Gadaleta","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jhepr.2021.100284_bib133","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/hep.31523","article-title":"The commensal microbe veillonella as a marker for response to an FGF19 analog in nonalcoholic steatohepatitis","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2021.100284_bib134","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1111\/liv.14620","article-title":"MAFLD vs NAFLD: let the contest begin!","volume":"40","author":"Bianco","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib135","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/liv.14711","article-title":"PCSK9 rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD","volume":"41","author":"Grimaudo","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib136","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1111\/liv.12707","article-title":"The UCP2-866 G > A promoter region polymorphism is associated with nonalcoholic steatohepatitis","volume":"35","author":"Fares","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2021.100284_bib137","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2011.05.029","article-title":"The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies","volume":"56","author":"Al-Serri","year":"2012","journal-title":"J\u00a0Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555921000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:25:43Z","timestamp":1762899943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555921000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2589555921000604"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100284","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2021.100284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"100284"}}